Treatment
Paclitaxel clinical trials
We’re tracking 669 recruiting studies that include Paclitaxel, each written for real people, not researchers, below.
Recruiting studies
- NCT06292286Recruiting
Second surgery for recurrent ovarian cancer that responds to platinum
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Hong KongAges 18 years+ - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Gilbert, ArizonaAges 18 years+ - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT06951997RecruitingPhase 2
First treatment for metastatic pancreatic cancer using three drugs
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
TianjinAges 18–75 - NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Mobile, AlabamaAges 18 years+ - NCT06942234RecruitingPhase 1/Phase 2
Study of JSKN016 for advanced HER2-negative breast cancer
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
ShanghaiAges 18–75 - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06914440RecruitingPhase 2
Radiation and immunotherapy before surgery for HR+/HER2- breast cancer
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Xi'an, Shannxi ProvinceAges 18–75 - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT05561114RecruitingPhase 3
Paclitaxel balloon to widen stubborn benign food pipe narrowing
This study tests whether a paclitaxel-coated balloon can keep the esophagus (food pipe) open longer in people with a stubborn benign narrowing. It aims to improve swallowing by reducing how often the narrowing needs repeat stretching.
Birmingham, AlabamaAges 22 years+ - NCT05561127RecruitingPhase 3
Paclitaxel balloon to treat stubborn non-cancer bowel narrowing
This trial studies a medicine-coated balloon (paclitaxel) placed during endoscopy to keep a non-cancer bowel narrowing (stricture) open longer. It may help reduce repeat procedures if standard balloon dilation hasn’t worked well enough.
Scottsdale, ArizonaAges 22 years+ - NCT06904378RecruitingPhase 1/Phase 2
New drug combo for advanced pancreatic cancer
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
St Louis, MissouriAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT05451043RecruitingPhase 2
Durvalumab and tremelimumab plus chemotherapy with propranolol
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
Edmonton, AlbertaAges 18 years+ - NCT06500208RecruitingPhase 2
Adebrelimab plus chemo before surgery for high-risk breast cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06897046RecruitingPhase 2
Study of Iparomlimab and Tuvonralimab for resectable lung cancer
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
BeijingAges 18 years+ - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT05272696RecruitingPhase 2
Pembrolizumab plus chemo before treatment for advanced head and neck cancer
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Guangzhou, GuangdongAges 18–70 - NCT06869226RecruitingPhase 2
Study of camrelizumab plus chemo before surgery for esophageal cancer
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
BeijingAges 18–75
Common questions
- Are there clinical trials studying Paclitaxel?
- Yes. Clin2 currently lists 669 recruiting studies that include Paclitaxel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Paclitaxel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Paclitaxel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Paclitaxel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.